Tom Taylor
Managing Associate
Europe
London
Tom is an intellectual property lawyer who advises clients on a wide range of IP matters. Tom focusses primarily on patent litigation and specialises in the high tech, engineering, electronics, TMT, and software sectors.
Tom is well experienced in advising clients across the IP spectrum and has recent experience in patent, copyright, and trade mark disputes. He is also experienced in life sciences patents and SPC related issues. He has experience of litigation in the Court of Appeal, the High Court, and IPEC.
Tom graduated from Imperial College London in 2009 with a first class MSci in Physics with Theoretical Physics. He then trained and qualified as a Solicitor at a magic circle firm before joining Marks & Clerk Law in November 2016.
Key Cases
- JCB v Manitou
- Manthorpe v Alumasc
- Add2 v dSPACE
- Genentech v the Comptroller General of Patents (High Court and Court of Appeal)
- Takeda v Roche
Languages
- English
Specialist in
Qualifications
Postgraduate Diploma in Intellectual Property Law and Practice, University of Oxford (2019)
Qualified as a Solicitor in England & Wales (2015)
Accelerated Legal Practice Course, BPP London (2013)
Graduate Diploma in Law, BPP London (2012)
MSci Physics with Theoretical Physics, Imperial College London (2009)
Search our people
Latest Insights
Marks & Clerk recognised again by The Legal 500 as a Top Tier Firm in their 2025 rankings
Marks & Clerk is delighted to have 35 practitioners recognised again by The Legal 500 in their newly released 2025 rankings.
Read more
Managing IP highlights seventeen Marks & Clerk practitioners in the 2024 IP STARS rankings
Marks & Clerk is delighted to announce that seventeen of our practitioners have been recognised in the 2024 IP STARS rankings.
Read more
Late-stage functionalisation: a unique perspective from a research scientist turned patent attorney
Late-stage functionalisation has emerged as a valuable enabling tool within the arsenal of a medicinal chemist. As newer synthetic methods become developed for the generation of small molecules, so too has the chemical space that medicinal chemists will have access to. Of course, these methods are valuable to the R&D team – but did you know that late-stage functionalisation will also likely have an impact on the IP profession?
Read more